Long-term VIVID-2 data show more than 90% of patients with Crohn’s disease who achieved steroid-free remission at one year maintained control through three years.

New data from Eli Lilly and Company reveal that mirikizumab (Omvoh) demonstrates durable efficacy in adults with moderately to severely active Crohn’s disease, maintaining steroid-free remission for up to three years. These findings were presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO) in Stockholm.

Additional results from the Phase 3 VIVID-1 (Crohn’s disease) and LUCENT-3 (ulcerative colitis) trials highlighted consistently low rates of hospitalisations and surgeries, suggesting mirikizumab could alter disease progression.

Adrienne Brown, executive vice president and president of Lilly Immunology, said: “Too many people with inflammatory bowel disease never achieve lasting remission, leaving them vulnerable to cumulative damage from poorly controlled inflammation that can result in emergency hospitalisations or surgery. Long-term data shows patients treated with mirikizumab stayed in remission and experienced fewer serious complications over three years, underscoring its potential to alter the course of the disease.”

VIVID-2 enrolled patients who had achieved an endoscopic response at one year in VIVID-1. Among these patients, 92.4% remained in clinical remission at 152 weeks, 91.2% maintained corticosteroid-free remission, and 82.1% experienced a ≥3-point reduction in bowel urgency severity. Edward Barnes, M.D. MPH, associate professor of medicine at the University of North Carolina at Chapel Hill, said: “Seeing more than 90% of patients maintain steroid-free remission through three years on consistent monthly dosing, with 80% also experiencing relief from the disruptive symptoms of bowel urgency, gives providers confidence in mirikizumab for outcomes that can last.”

The analysis also showed sustained reductions in inflammatory biomarkers, including C-reactive protein and faecal calprotectin, with a safety profile consistent with previous trials. Common adverse events were mild, including COVID-19, nasopharyngitis, and upper respiratory tract infection.

Across the VIVID and LUCENT programmes, mirikizumab also demonstrated low rates of hospitalisation and surgery in both Crohn’s disease and ulcerative colitis, reinforcing its potential to provide long-term disease control.

Mirikizumab is a humanised IgG4 monoclonal anti‑interleukin‑23 antibody that selectively binds the p19 subunit of IL‑23, inhibiting the IL‑23/IL‑23 receptor pathway implicated in T cell‑driven inflammation.